A Phase 2 interventional study of JWK001 and Aflibercept (2.0 mg) in Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD, sponsored by West China Hospital. Recruiting at 16 sites in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by West China Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.
Among the 106 studies in Macular Degeneration with a site in China, this one is the 50th largest by planned enrollment of the 91 interventional ones that give a count, is one of 8 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 31 of the 42 other live ones, and was the 106th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in China, United States, Argentina and 16 more countries
Ages 50+
Innostellar Biotherapeutics Co.,Ltd · Sites in China
Ages 50–80
Innovent Biologics Technology Limited (Shanghai R&D Center) · Sites in China
Ages 50+
Peking University People's Hospital · Sites in China
Ages 50+
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 50–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 36 · Phase 3 22 · Phase 4 5
First in 2008; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 62 across the 91 interventional studies, 300 across the 15 observational. Of the 39 that completed or were terminated, 6 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 106 have an industry lead sponsor. The 10 most frequent:
West China Hospital is the lead sponsor of 503 studies on the registry; 247 are open to participants now.
West China Hospital has 1 study filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
11 of the studies in Macular Degeneration with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05972473Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD | 2027-02-28 |
| NCT07189169Phase 3Smilebiotek Zhuhai LimitedQA108 Phase III Study in Subjects With Intermediate AMD | 2027-03-01 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT07053358Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSafety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients | 2026-11-23 |
| NCT07409389The Hong Kong Polytechnic UniversityRepeated Low-Level Red-Light Therapy in Dry Age-Related Macular Degeneration | 2026-12-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 106 studies in Macular Degeneration with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase II, randomized, open-label, active-controlled study designed to evaluate the preliminary efficacy and safety of a single subretinal administration of JWK001 at different dose levels in patients with neovascular age-related macular degeneration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will receive a single subretinal injection of JWK001 at a dose of 3 × 10\^10 vector genomes (vg) in one study eye.
Drug: JWK001
Participants assigned to this arm will receive a single subretinal injection of JWK001 at a dose of 6 × 10\^10 vector genomes (vg) in one study eye.
Drug: JWK001
Participants assigned to this arm will receive aflibercept 2 mg by intravitreal injection at Weeks 2, 10, 18, 26, 34, 42, and 50 after randomization.
Drug: Aflibercept (2.0 mg)
JWK001 will be administered as a single subretinal injection in one study eye.
Aflibercept 2 mg will be administered by intravitreal injection at Weeks 2, 10, 18, 26, 34, 42, and 50 after randomization, for a total of seven injections.
Change from baseline in best-corrected visual acuity (BCVA)
BCVA measured via the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score
Time frame: Week 34
Change from baseline in BCVA
BCVA measured via the ETDRS letter score
Time frame: Week 50 and Year 5
Change from baseline in central retinal thickness (CRT)
Time frame: Week 34, Week 50 and Year 5
Change from baseline in the area of Macular Neovascularization (MNV)
MNV measured via Fluorescein Angiography (FFA)
Time frame: Week 34 and Week 50
Change from baseline in leakage area
Leakage area assessed by FFA
Time frame: Week 34 and Week 50
Annualized mean number of rescue treatments
Time frame: Week 34, Week 50 and Year 5
Change from baseline in the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) score
NEI VFQ-25 composite score ranges from 0 to 100. Higher scores indicate better vision-related functioning and quality of life. A positive change from baseline indicates improvement, whereas a negative change indicates worsening.
Time frame: Week 34 and Week 50
Frequencies and severities of all safety events
Time frame: Week 34 and Year 5
Neutralizing Antibodies (NAbs) Titer Against the Adeno-Associated Virus Serotype 8(AAV8) Capsid
NAbs titer against the AAV8 capsid protein will be assessed in blood samples. Higher titers indicate a stronger neutralizing antibody response.
Time frame: Week 50
Anti-Drug Antibody (ADA) Titer Against the nVEGF1 Protein
ADA titers against the nVEGF1 protein expressed by JWK001 will be measured in blood samples. Higher titers indicate a stronger anti-drug antibody response.
Time frame: Week 50
T-Cell Immune Response Against the AAV8 Capsid Protein
T-cell immune responses against the AAV8 capsid protein will be assessed using an enzyme-linked immunospot (ELISpot) assay.
Time frame: Week 50
T-Cell Immune Response Against the nVEGF1 Protein
T-cell immune responses against the nVEGF1 protein will be assessed using an enzyme-linked immunospot (ELISpot) assay.
Time frame: Week 50
JWK001 Vector DNA Level in Blood
JWK001 vector DNA will be measured in blood samples.
Time frame: Week 4
JWK001 Vector DNA Level in Tears
JWK001 vector DNA will be measured in tear samples
Time frame: Week 4
JWK001 Vector DNA Level in Urine
JWK001 vector DNA will be measured in urine samples
Time frame: Week 4
JWK001 Vector DNA Level in Feces
JWK001 vector DNA will be measured in fecal samples
Time frame: Week 4
Concentration of the nVEGFi Transgene Expression Product in Blood
The concentration of the nVEGFi transgene expression product will be measured in blood samples
Time frame: Week 50
Concentration of the nVEGFi Transgene Expression Product in Aqueous Humor
The concentration of the nVEGFi transgene expression product will be measured in aqueous humor samples
Time frame: Week 104
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Aug 2027, 11 months later.
Of 83 phase 2 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 35. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.